The Food and Drug Administration (FDA) has recently approved several medications for the treatment of NSCLC, of which the primary targets for kinase inhibitor therapy in NSCLC have now targeted activation of EGFR, ALK, ROS1, and BRAF, MET, and RET (Figure 1). This evidence concerns the gene RET and non-small cell lung carcinoma.